Shay Shemesh - 06 Jan 2026 Form 4 Insider Report for Nuvectis Pharma, Inc. (NVCT)

Reporting relationship: Chief Dev. & Ops. Officer
Issuer ticker: NVCT
Reported as of: 06 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jan 2026, 16:32:18 UTC
Prior SEC filing: 03 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Shay Shemesh

Key filing fact

Shay Shemesh filed Form 4 for Nuvectis Pharma, Inc. (NVCT) on 09 Jan 2026.

Key facts

This page summarizes Shay Shemesh's Form 4 filing for Nuvectis Pharma, Inc. (NVCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Jan 2026, 16:32.

Change

Previous filing in this sequence was filed on 03 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001896056 Primary reporting owner

Shemesh Shay

Relationship: Chief Dev. & Ops. Officer
Address: C/O NUVECTIS PHARMA, INC., 1 BRIDGE PLAZA, SUITE 275, FORT LEE
Signature: /s/ Shay Shemesh
Signature date: 09 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVCT transaction

Common Stock

Award

Transaction value: $0
Shares: +150,000
Change %: +9.1%
Price: $0.000000
Shares after: 1,793,068
Date: 06 Jan 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Shemesh's continued service on such dates.

Footnote F2

Includes shares of restricted common stock.